The Abbott Tendyne Transcatheter Mitral Valve Implantation (TMVI)system received the European CE mark. It is the first transcatheter mitral valve replacement (TMVR) technology in the world. Aim: The main aim is to make critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option in high-risk surgical patients. Abbott: Abbott is developing a transcatheter mitral valve to open-heart surgery. Building upon its success with the MitraClip device and many years of mitral valve experience and clinical evidence.
Current Affairs Calender
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | |